Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy

Smith, Jonathan; Steel, David

doi:10.1002/14651858.cd008214.pub3

Cited by 77 publications

(47 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of pre- or intraoperative bevacizumab also lowered the incidence of early postoperative vitreous cavity hemorrhages [13]. Vitrectomy with preoperative IVB decreased intraoperative hemorrhages and surgical times and reduced postoperative vitreous hemorrhage rates [14].…”

Section: Discussionmentioning

confidence: 99%

Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients

Feng

Wen

et al. 2018

Ophthalmic Res

View full text Add to dashboard Cite

Objective: To evaluate the changes in aqueous concentrations of inflammatory cytokines and fibrosis-related factors, and to detect the expression of vascular endothelial growth factor (VEGF) and proliferating cells in fibrovascular membranes (FVMs) of patients with proliferative diabetic retinopathy (PDR) after injection of intravitreal bevacizumab (IVB). Methods: Forty-two eyes of 42 patients with PDR, including 28 eyes that received IVB (1.25 mg) 2, 5, and 14 days before pars plana vitrectomy (PPV), and 14 eyes without IVB, were enrolled, in addition to 10 eyes of 10 patients with nondiabetic ocular diseases. Aqueous concentrations of inflammatory cytokines and fibrosis-related factors were analyzed by a multiplex bead assay. Fluorescence immunostaining was performed to examine the expression of VEGF and proliferating cells in the excised epiretinal membranes. Results: PDR eyes without IVB had the highest vitreous VEGF levels, and the level was statistically significant compared with that of PDR eyes that received IVB 2 days before surgery, PDR eyes that received IVB 5 days before surgery, and nondiabetic eyes (p = 0.011, p = 0.012, and p < 0.001, respectively). The expression of fibroblastic cells and connective tissue growth factor increased in epiretinal FVMs of the IVB group 21 days after treatment. Conclusions: IVB injection may lead to a decrease in the intraocular concentrations of VEGF after 2–5 days and induce the formation of proliferation after 21 days, which suggests that PPV in PDR patients should take place within 1 week of the administration of preoperative IVB.

show abstract

Section: Discussionmentioning

confidence: 99%

Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients

Feng

Wen

et al. 2018

Ophthalmic Res

View full text Add to dashboard Cite

show abstract

“…RNV is a common feature of ischemic retinopathies, including retinopathy of prematurity (ROP), central retinal vein occlusion (CRVO), and proliferative retinopathy (PDR) [2–4]. A mouse model of oxygen-induced retinopathy (OIR), which is consistent and reliable at quantifying RNV, has been used extensively [5, 6].…”

Section: Introductionmentioning

confidence: 99%

Suppression of Retinal Neovascularization by Inhibition of Galectin-1 in a Murine Model of Oxygen-Induced Retinopathy

Yang

Zhang

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

Galectin-1 (Gal-1) has been proved to be an important factor in the process of tumor angiogenesis recently. As a small molecule, OTX008 serves as a selective inhibitor of Gal-1. In this study, the role of Gal-1 and the antiangiogenic effect of OTX008 on retinal neovascularization (RNV) were investigated using a mouse model of oxygen-induced retinopathy. The outcome indicated that Gal-1 was overexpressed and closely related to retinal neovessels in OIR. After intravitreal injection of OTX008 at P12, the RNV was significantly reduced at P17, measuring by cross-sectional H&E staining and whole-mount fluorescence. Our results demonstrate the inhibitory function of OTX008 on RNV, which provides a promising strategy of treating retinal angiogenic diseases such as retinopathy of prematurity and proliferative diabetic retinopathy.

show abstract

“…2015 hat eine Cochrane-Analyse von 12 randomisierten kontrollierten Studien den Vorteil der präoperativen Anti-VEGF-A-Injektion (Bevacizumab, Ranibizumab und Aflibercept) mit dem Effekt der verminderten postoperativen Glaskörperblutung und einem verminderten Risiko für Netzhautablösung bestätigt [1]. …”

Section: Transfer In Die Praxis Von Prof Dr Olaf Strauß (Berlin)unclassified

IVOM mit Bevacizumab vor der Parsplana-Vitrektomie bei Patienten mit proliferativer diabetischer Retinopathie

Strauß¹

2019

Kompass Ophthalmol

View full text Add to dashboard Cite

Objective: To evaluate the changes in aqueous concentrations of inflammatory cytokines and fibrosis-related factors, and to detect the expression of vascular endothelial growth factor (VEGF) and proliferating cells in fibrovascular membranes (FVMs) of patients with proliferative diabetic retinopathy (PDR) after injection of intravitreal bevacizumab (IVB). Methods: Forty-two eyes of 42 patients with PDR, including 28 eyes that received IVB (1.25 mg) 2, 5, and 14 days before pars plana vitrectomy (PPV), and 14 eyes without IVB, were enrolled, in addition to 10 eyes of 10 patients with nondiabetic ocular diseases. Aqueous concentrations of inflammatory cytokines and fibrosis-related factors were analyzed by a multiplex bead assay. Fluorescence immunostaining was performed to examine the expression of VEGF and proliferating cells in the excised epiretinal membranes. Results: PDR eyes without IVB had the highest vitreous VEGF levels, and the level was statistically significant compared with that of PDR eyes that received IVB 2 days before surgery, PDR eyes that received IVB 5 days before surgery, and nondiabetic eyes (p = 0.011, p = 0.012, and p < 0.001, respectively). The expression of fibroblastic cells and connective tissue growth factor increased in epiretinal FVMs of the IVB group 21 days after treatment. Conclusions: IVB injection may lead to a decrease in the intraocular concentrations of VEGF after 2-5 days and induce the formation of proliferation after 21 days, which suggests that PPV in PDR patients should take place within 1 week of the administration of preoperative IVB.

show abstract

Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy

Abstract: Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Cited by 77 publications

References 84 publications

Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients

Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients

Suppression of Retinal Neovascularization by Inhibition of Galectin-1 in a Murine Model of Oxygen-Induced Retinopathy

IVOM mit Bevacizumab vor der Parsplana-Vitrektomie bei Patienten mit proliferativer diabetischer Retinopathie

Contact Info

Product

Resources

About